-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Derazantinib Hydrochloride in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Derazantinib Hydrochloride in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Derazantinib Hydrochloride in Solid Tumor Drug Details: Deranzantinib hydrchloride (ARQ-087)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Lung Cancer Drug Details: AFM-24I is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Alisertib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alisertib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in Non-Small Cell Lung Cancer Drug Details: Alisertib (MLN-8237)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Neratinib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neratinib in Non-Small Cell Lung Cancer Drug Details: Neratinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alisertib in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alisertib in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in Small-Cell Lung Cancer Drug Details: Alisertib (MLN-8237) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-764532 in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-764532 in Neuroendocrine Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-764532 in Neuroendocrine Carcinoma Drug Details: OBT-620 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDB-001 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDB-001 in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDB-001 in Melanoma Drug Details: BDB-001 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDB-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDB-001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDB-001 in Solid Tumor Drug Details: BDB-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDB-001 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDB-001 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDB-001 in Renal Cell Carcinoma Drug Details: BDB-001 is under...